REPARE THERAPEUTICS INC (RPTX)

Company Profile

Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 180 full-time employees. The company went IPO on 2020-06-19. The firm is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. The company uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Company Info

REPARE THERAPEUTICS INC

7210 Frederick-Banting, Suite 100

ST-LAURENT QUEBEC H4S 2A1

P: 18574127018

CEO: Lloyd M. Segal

Employees: 180

Website: https://www.reparerx.com/